@pharmafocusasia offecial Racthera co, Ltd. website racthera.com #SumitomoChemical #SumitomoPharma #RACTHERA
English
Atom
3.4K posts
Academic hospitals + AI = The future of ATMPs! With AI, institutions can now meet GMP standards while developing next-gen cell & gene therapies in-house.
Explore how #AI boosts safety, speed & compliance
🔗pharmafocusasia.com/information-te…
#ATMP #GeneTherapy #AIinPharma #GMP #CellTherapy
English
@GeneOnlineNews offecial Racthera co, Ltd. website racthera.com #SumitomoChemical #SumitomoPharma #RACTHERA
English
🧬 GeneOnline continued its journey with a visit to Sumitomo Pharma, a historic name in Japanese pharma with roots dating back to 1897! 🇯🇵💊 A special mention to BPIPO and the Development Center for Biotechnology (DCB) for their support in fostering collaboration and innovation between Taiwan and Japan's biotech sectors. 🤝🏻
🧪 Sumitomo Pharma’s allogeneic iPS cell therapy for Parkinson’s disease, CT1-DAP001 (DSP-1083), has entered the NDA preparation phase in Japan and received the Sakigake designation for accelerated review. 🔍 The company is also running early-stage trials for retinal diseases (DSP-3077, HLCR011) and driving CNS drug discovery through AI partnerships with Exscientia and academic collaborations with Kyoto University, UCSD, and Massachusetts Eye & Ear. 🔬💡
Our visit also introduced us to Racthera Co., Ltd., a new JV formed after the 2024 group reorganization between Sumitomo Chemical and Sumitomo Pharma. Launched officially in February 2025, Racthera focuses on advancing regenerative and cell therapy solutions. 🧫🚀
In addition, we learned about S-RACMO Co., Ltd., their joint CDMO venture established in 2020. S-RACMO offers end-to-end manufacturing services for iPS, ES, and somatic stem cells, supporting both autologous and allogeneic therapies, with a growing footprint in gene therapy. 🧠🔧
Thank you, Sumitomo Pharma, for the warm welcome! 👏🏻 ✨
📩 Stay ahead of the game! Get the latest biotech insights straight to your inbox—subscribe now! 👇🏻bit.ly/486XjUU
#GeneOnlineOnTheMove #SumitomoPharma #Racthera #SRACMO #CellTherapy #RegenerativeMedicine #iPSCells #GeneOnline #biotrends
English
English
English
Sumitomo Chemical Co., Ltd. and Sumitomo Pharma Co., Ltd. have taken a significant step in accelerating the development of regenerative #medicine and cell therapy by forming a joint venture, RACTHERA Co. Ltd.
tinyurl.com/478pbvbd
#SumitomoChemical #SumitomoPharma #RACTHERA
English
@elonmusk i think you interest to buy our domains abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
These are unmodified Tesla cars coming straight from the factory, meaning that every Tesla coming out of our factories is capable of unsupervised self-driving!
Elon Musk@elonmusk
Beautifully simple design.
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
@elonmusk
i think you interest to buy our domains
abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it americanbtc.co.it americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk i think you interest to buy our domains abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
@elonmusk
i think you interest to buy our domains
abtc.co.it
americanbtc.co.it
americanbitcoin.co.it
English
出願日：2024-11-12
出願人：住友化学株式会社,SUMITOMO CHEMICAL COMPANY,LIMITED
区分：第1類(化学品),第5類(薬剤),第9類(機械器具) ほか4
商品役務：研究用幹細胞,科学用幹細胞,幹細胞(医療用及び獣医科用のものを除く。) ほか123
OCRテキスト2：RACTHERA
続き chizai-watch.com/t/2024121231
日本語
＜#再生医療 日本発・世界初に挑戦＞
日本の現在地と課題は？
日本再生医療学会の岡野栄之理事長と（写真左）と、ＲＡＣＴＨＥＲＡの池田篤史社長（写真右）に認識を聞いた。 – #化学工業日報電子版
chemicaldaily.com/archives/632110
日本語